VistaGen Therapeutics, Inc.
VTGN
Rank in Stocks
#29307
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity... VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
Share Price
$0.1844
Last synced: 2026-11-09
Market Cap
$8.18M
Change (1 day)
12.58%
Change (1 year)
-95.47%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade VistaGen Therapeutics, Inc. (VTGN)
Category
Healthcare
Operating Margin for VistaGen Therapeutics, Inc. (VTGN)
Operating Margin as of November 2026 TTM: -2,784.33%
According to VistaGen Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -2,784.33%. At the end of 2025 the company had an operating margin of -11,517.08%.
Operating Margin history for VistaGen Therapeutics, Inc. from 2007 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -2,784.33% | -75.82% |
| 2025 | -11,517.08% | 271.10% |
| 2024 | -3,103.48% | -111.89% |
| 2023 | 26,109.25% | -705.97% |
| 2022 | -4,308.68% | 161.76% |
| 2021 | -1,646.06% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | -100.00% |
| 2017 | -819.88% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | -100.00% |
| 2013 | -3,389.77% | 403.10% |
| 2012 | -673.77% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.01% |
US
|
|
| -149.01% | -99.95% |
US
|
|
| 25.57% | -100.01% |
AU
|
|
| 31.23% | -100.01% |
BE
|
|
| 29.35% | -100.01% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about VistaGen Therapeutics, Inc.'s operating margin
What is VistaGen Therapeutics, Inc.'s operating margin?
VistaGen Therapeutics, Inc.'s operating margin is -2,784.33%, as of Nov 2026.
What was VistaGen Therapeutics, Inc.'s operating margin in 2025?
In 2025, VistaGen Therapeutics, Inc.'s operating margin was -11,517.08%, compared with -3,103.48% in 2024.
How has VistaGen Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, VistaGen Therapeutics, Inc.'s operating margin was highest in 2023 (26,109.25%) and lowest in 2025 (-11,517.08%).
How does VistaGen Therapeutics, Inc.'s operating margin compare with similar companies?
VistaGen Therapeutics, Inc.'s operating margin (-2,784.33%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.